International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
The International Myeloma Working Group (IMWG) provides a statement on autologous stem cell support (ASCT). This statement explains how multiple myeloma calls for high-dose chemotherapy with ASCT most commonly in North America as of present. Generally, this is executed by collecting at least 2 million CD34+ cells/kg per one cycle of high-dose therapy. The International Myeloma Foundation had a group of experts meet on June 1, 2008, in order to discuss how to execute stem cell collection with the new prevalence of advent of plerixafor (AMD 3100).
Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Kumar S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Jagannath S, Blade J, Lonial S, Dimopoulos MA, Einsele H, Barlogie B, Anderson KC, Gertz M, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardson PG, Niesvizky R, Rajkumar SV, Durie BG; IMWG.
Click here to view article: